129 related articles for article (PubMed ID: 17285456)
1. American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Clemetson KJ
IDrugs; 2007 Feb; 10(2):90-2. PubMed ID: 17285456
[No Abstract] [Full Text] [Related]
2. American Society of Hematology--48th Annual Meeting and Exposition. Treatments for leukemia and lymphoma. 9-12 December 2006 Orlando, FL, USA.
Talmadge JE
IDrugs; 2007 Feb; 10(2):87-9. PubMed ID: 17285455
[No Abstract] [Full Text] [Related]
3. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):84-6. PubMed ID: 17285454
[No Abstract] [Full Text] [Related]
4. American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):78-80. PubMed ID: 17285452
[No Abstract] [Full Text] [Related]
5. American Society of Hematology--48th Annual Meeting and Exposition. 9-12 December 2006, Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):75-7. PubMed ID: 17285451
[No Abstract] [Full Text] [Related]
6. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Thompson N; Lyons J
Curr Opin Pharmacol; 2005 Aug; 5(4):350-6. PubMed ID: 15955734
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib - a small molecule with big promise?
Tadmor T; Tallman MS; Polliack A
Leuk Lymphoma; 2010 Feb; 51(2):181-2. PubMed ID: 20001865
[No Abstract] [Full Text] [Related]
8. American Society of Hematology--48th Annual Meeting and Exposition. The Factor Xa target, and disorders of platelet number and function. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):81-3. PubMed ID: 17285453
[No Abstract] [Full Text] [Related]
9. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Voigtmann R; Schwartz B; Brendel E; Christensen O; Haase CG; Strumberg D
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):650-1. PubMed ID: 15598035
[No Abstract] [Full Text] [Related]
10. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Walz C; Erben P; Ritter M; Bloor A; Metzgeroth G; Telford N; Haferlach C; Haferlach T; Gesk S; Score J; Hofmann WK; Hochhaus A; Cross NC; Reiter A
Blood; 2011 Aug; 118(8):2239-42. PubMed ID: 21705501
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
13. About sorafenib in castration-resistant prostate cancer.
Colloca G; Checcaglini F; Venturino A
Ann Oncol; 2008 Oct; 19(10):1812-3; author reply 1813-1814. PubMed ID: 18689865
[No Abstract] [Full Text] [Related]
14. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
[TBL] [Abstract][Full Text] [Related]
15. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
16. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Wu CH; Wu X; Zhang HW
J Surg Res; 2016 Dec; 206(2):371-379. PubMed ID: 27884331
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
19. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights II.
Evans L
IDrugs; 2005 Jan; 8(1):10-3. PubMed ID: 15650933
[No Abstract] [Full Text] [Related]
20. Sorafenib is active on lung metastases from synovial sarcoma.
Basso U; Brunello A; Bertuzzi A; Santoro A
Ann Oncol; 2009 Feb; 20(2):386-7. PubMed ID: 19211500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
